PTC Therapeutics (PTCT) is back in focus after reporting 24-month interim data from the PIVOT-HD extension study of votoplam in Huntington’s disease, highlighting dose-dependent slowing of progression ...

Analysts have made only a slight adjustment to their fair value view on PTC Therapeutics, with the target moving from $87.87 to $88.07 per share. That small change reflects a mix of bullish and ...

Phase 2 data from PTC Therapeutics showed that the Novartis-partnered Huntington’s disease asset slowed progression by more ...

PTC Therapeutics, Inc. (NASDAQ:PTCT) ranks among the most profitable biotech stocks to buy now. On April 28, PTC Therapeutics ...

PTC Therapeutics Inc. PTCT shares are tumbling on Wednesday, after the company reported topline results from the 24-month ...

SOUTH PLAINFIELD, N.J., March 30, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the initiation of the PIVOT-HD Phase 2 clinical trial evaluating PTC518 in people with ...

PTC518 treatment resulted in the lowering of mutant huntingtin protein in the blood and cerebrospinal fluid. Furthermore, after 12 months of treatment, PTC518 remains safe and well tolerated. Ready to ...

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Okta Inc (Symbol: OKTA), where a total of 9,766 contracts have traded so far, representing ...

PTC Therapeutics Inc. CEO Matthew Klein said the firm “achieved all we set out to [achieve] in phase II” with PTC-518 in Huntington’s disease (HD), but it wasn’t enough to excite Wall Street, as some ...

SOUTH PLAINFIELD, N.J., June 21, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today shared interim data from the 12-week portion of the PIVOT-HD Phase 2 study of PTC518 in Huntington's disease ...

What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for ...

Novartis and PTC Therapeutics are advancing their Huntington’s disease drug, votoplam, into a Phase 3 trial after mid-stage data showed it slowed disease progression by up to 52%. The move signals ...